Analysis finds abelacimab cuts bleeding in patients on APT versus rivaroxaban

Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban.

The privately-held Boston, USA-based firm is a biopharma developing therapies for cardiovascular metabolic diseases. Founded by Blackstone Life Sciences in 2019, the company has exclusive global rights from Swiss pharma giant Novartis (NOVN: VX) to develop, manufacture and commercialize abelacimab, a novel factor XI inhibitor.

Discussing the new analysis, Christian Ruff, senior investigator of TIMI Group and director general Cardiology, Cardiovascular Division, Brigham and Women's Hospital, said: “Given the elevated bleeding risks associated with traditional anticoagulants, particularly when combined with antiplatelet agents, abelacimab may offer a safer alternative for patients with atrial fibrillation.